Role of Combination of Sacubitril and Valsartan for Management of Patients with Decompensated Heart Failure


  • Author- Waqar Ahmad, Anas Sajjad, Farwa Abbas, Amna Riaz, Rae Hasnain Shehzad, Iqra Waheed


Objective: To determine the outcome of sacubitril plus valsartan in patients with decompensated heart failure


This quasi experimental study was done at Department of Cardiology, Mayo Hospital, Lahore during March 2022 to March 2023. Total 200 patients with decompensated heart failure were enrolled through emergency and admitted in cardiology wards. All patients were given Sacubitril / valsartan (200 mg, twice daily) during hospital stay. Then all patients were followed-up until discharge from the hospital. If patient died during hospital stay, then mortality was noted. data was colelcted in proforma whiel analysed in SPSS version 25.


  In this trial, we enrolled total 200 individuals with decompensated heart failure with mean age of 55.02 ± 8.64 years. Out of 200 individuals, 111 (55.5%) were males and 89 (44.5%) were females. Out of 200 individuals, 34 (17.0%) individuals died during follow-up in the hospital after receiving sacubitril with valsartan combination drug. For ejection fraction, the mortality was significantly higher in individuals who had ejection fraction less than 22% (27.9%) as compared to individuals with ejection fraction was higher than 22% (3.4%, p-value < 0.05).


 The outcome of sacubitril with valsartan combination drug is better and morality is less.


in-hospital mortality, sacubitril, valsartan, decompensated heart failure